Education
About Us
Working with TipRanks
Follow Us
CASI Pharmaceuticals (CASI)
NASDAQ:CASI
CASI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.09 - $7.50
Previous CloseN/A
Volume17.83K
Average Volume (3M)314.68K
Market Cap
$27.58M
Enterprise Value$30.27M
Total Cash (Recent Filing)$20.81M
Total Debt (Recent Filing)$19.12M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 12, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding15,492,681
10 Day Avg. Volume73,165
30 Day Avg. Volume314,676
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue1.42
Enterprise Value/Gross Profit2.58
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$4.00Price Target Upside124.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Debt ReductionThe sale of the China business to Kaixin allows the company to eliminate $20M of existing debt, improving its financial position.
Product DevelopmentCID-103 has shown superior activity and reduced toxicity compared to existing CD38 inhibitors in preclinical and Phase 1 studies, indicating strong potential for successful development.
Strategic ManagementThe appointment of David Cory as the company’s new CEO, who has more than 30 years of experience in the biotech and pharma sectors, is seen as beneficial for the company’s new direction.
Bears Say
Financial PerformanceCASI reported revenues of $4.2M and a net loss of $0.86 per share for the quarter, which was below the consensus estimated revenue of $6.3M and net loss of $0.47 per share.
Licensing And RevenueThe company received a Termination Process Letter to withdraw the Evomela license following a wind-down period, which impacts the company's Chinese business revenues.
Revenue ImpactThe company reported lower-than-expected revenues, which fell 16% year-over-year, primarily due to increased generic competition for Evomela in China.
CASI Pharmaceuticals News
CASI FAQ
What was CASI Pharmaceuticals’s price range in the past 12 months?
CASI Pharmaceuticals lowest stock price was $1.09 and its highest was $7.50 in the past 12 months.
What is CASI Pharmaceuticals’s market cap?
CASI Pharmaceuticals’s market cap is $27.58M.
When is CASI Pharmaceuticals’s upcoming earnings report date?
CASI Pharmaceuticals’s upcoming earnings report date is Nov 12, 2025 which is in 53 days.
How were CASI Pharmaceuticals’s earnings last quarter?
CASI Pharmaceuticals released its earnings results on Aug 29, 2025. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.47 by -$0.39.
Is CASI Pharmaceuticals overvalued?
According to Wall Street analysts CASI Pharmaceuticals’s price is currently Undervalued.
Does CASI Pharmaceuticals pay dividends?
CASI Pharmaceuticals does not currently pay dividends.
What is CASI Pharmaceuticals’s EPS estimate?
CASI Pharmaceuticals’s EPS estimate is -0.4.
How many shares outstanding does CASI Pharmaceuticals have?
CASI Pharmaceuticals has 15,492,681 shares outstanding.
What happened to CASI Pharmaceuticals’s price movement after its last earnings report?
CASI Pharmaceuticals reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.47. Following the earnings report the stock price went down -0.433%.
Which hedge fund is a major shareholder of CASI Pharmaceuticals?
Currently, no hedge funds are holding shares in CASI
CASI Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (124.72% Upside)
$4.00 (124.72% Upside)
Blogger Sentiment
Bullish
CASI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-73.66%
12-Months-Change
Fundamentals
Return on Equity
-1094.50%
Trailing 12-Months
Asset Growth
-41.45%
Trailing 12-Months
Company Description
CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
CASI Stock 12 Month Forecast
Average Price Target
$4.00
▲(124.72% Upside)
Technical Analysis
Ownership Overview
9.20%
Insiders
0.12% Mutual Funds
13.66% Other Institutional Investors
77.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---